Issue link: http://osercommunicationsgroup.uberflip.com/i/808992
Chain Drugstore Daily Monday, April 24, 2017 2 8 superior comfort and protection over time for enhanced relief for dry eye suf- ferers. Rohto Dry-Aid effectively addresses the five key symptoms of dry eye: dry- ness, irritation, grittiness, burning and stinging. In clinical studies, it demon- strated its consistent ability to improve the signs and symptoms of dry eye. The clear, non-blurring formula was also rated highly for its refreshing feeling while delivering significant improve- ments in quality of life measures. "Rohto Dry-Aid is our most advanced eye drop formula," says Erick Estrada, Senior Marketing Director. "Our global research and development team has created a proprietary technolo- gy that delivers superior comfort and longer lasting relief for dry eye than the leading brand in a non-blurry eye drop. The tear film break up pattern of dry eye patients leads to premature tear evapora- tion followed by discomfort. Unlike most OTC dry eye drops that only work on the aqueous layer, which is the mid- dle layer of the tear film, Rohto Dry-Aid is specially formulated with Liquidshield™ technology that works in a unique way to help restore moisture to Rohto (Cont'd. from p. 1) the tear film by working on all three lay- ers to mimic a natural healthy tear, soothing eyes for up to 12 hours." In addition to delivering an advanced formula for dry eye sufferers, Rohto Dry-Aid will accelerate the Dry Eye segment growth by attracting younger consumers. "Dry eye is no longer associated with older consumers. Today's connected lifestyles mean more screen time than ever. Because of that, we are seeing younger age groups driving dry eye growth. Fifty-four percent of all dry eye consumers are between the ages of 18 to 54," Estrada says. "Given the high affinity younger consumers have for our core redness and multi-symptom SKUs, Rohto Dry-Aid is uniquely posi- tioned to attract more Millennials and Gen Xers to the category. Rohto will be effectively reaching this target with a rel- evant and massive multi-media cam- paign." In addition to Rohto Dry-Aid, the Rohto brand offers a full line of eye care products that provide fast relief for a variety of symptoms to help keep eyes looking and feeling great. For more information, visit booth #314, go to www.rohtoeyedrops.com or find the company on Facebook and Twitter. products. This type of high fidelity prod- uct data has never been more important. Label Insight's data allows us to enrich and enhance retailers' internal sys- tems so they can better understand their product inventory and set their owned brands up for future success at the shelf versus national brand competitors. Label Insight also helps retailers optimize their omni-channel experiences in response to consumer demand for a seamless shop- ping experience across physical and dig- ital properties. This data fuels website search functionality, recommendation engines and online searchability. CDD: What are the biggest retail trends you're seeing today? AK: More sophisticated health and well- ness initiatives. Many retailers are look- ing to improve their health and wellness initiatives and create better shopping experiences for people seeking specific foods like gluten-free or heart healthy, or personal products that are fragrance-free or sulfate-free. Label Insight helps retail- ers focus on the specific set of product attributes that matter to them. Once these attributes are identified and understood, retailers can analyze their inventory to identify which products meet specific H&W standards, and create a more con- nected omni-channel experience provid- ing consistent H&W info across all chan- nels – in-store, mobile, online and more. Drive towards greater transparency with SmartLabel™. SmartLabel is not just for large CPG brands. Retailers are answering the call for product trans- parency with their owned brands in order to create stronger connections with their Label Insight (Cont'd. from p. 1) customers and create long term loyalty. CDD: What's the opportunity with SmartLabel for non-food brands? AK: Nearly four in 10 consumers say they would switch to a new brand from a current preferred brand in favor of increased product transparency, and 73 percent of consumers would be willing to pay more for a product that offers com- plete transparency, according to a recent survey by Label Insight. The demand for transparency is clear, yet one of the most challenging categories in which to find information is personal care products. Consumer desire for transparency is universal, and the opportunity for retail- ers to satisfy consumer demand for trans- parency within their owned brand per- sonal care products will be a huge com- petitive advantage and will help owned brands drive growth. One great example of a company who has answered the call for transparency in personal care products is Unilever. Along with personal care brands such as Dove, Degree and Suave participating in SmartLabel, Unilever has launched a much lauded new fragrance transparency initia- tive for its personal care brands, voluntari- ly expanding its current product ingredient lists available through SmartLabel this year to include the fragrance ingredients in a product's formulation above 0.01%. The true opportunity with trans- parency is to better connect with con- sumers. It pays off in the form of increased brand loyalty and perceived brand worth. For more information, go to www.labelinsight.com or call 888.787.4386 x132. Osteoarthritis (KOA) patients per year. "As we have previously stated, this marks a key milestone in our corporate development in the first quarter of 2017 as we continue to invest in and expand our capabilities in advanced CAR-T and stem cell manufacturing. We have long recognized the logistical challenges of delivering consistent, quality and clinical grade processes to deliver cell therapies to market and we have differentiated our capabilities to meet this challenge. We will now be able to centralize, standard- ize and automate our manufacturing capabilities fully in-house while enhanc- ing our capacity to meet the production demands of multiple products in devel- opment as part of our overall Chemistry, Manufacturing and Controls ('CMC') process," said Tony (Bizuo) Liu, Chief Executive Officer of Cellular Biomedicine Group. "The Wuxi facility is equipped with six independent production lines and will be capable of producing and banking low endotoxin high transfection rate plas- mids, and high titer automated and puri- fied virus with stringent quality control," commented Helen Zhang, Senior Vice President of Technology and Manufacturing for CBMG. CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China Cellular Biomedicine (Cont'd. from p. 1) for AlloJoin™ (CBMG's "Off-the-Shelf" Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treat- ment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to sup- port pre-clinical studies of AlloJoin for Knee Osteoarthritis in the United States. About Cellular Biomedicine Group Cellular Biomedicine Group, Inc. devel- ops proprietary cell therapies for the treatment of cancer and degenerative diseases. It conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. Its GMP facilities in China, consisting of twelve independent cell production lines, are designed and man- aged according to both China and U.S. GMP standards. CBMG recently com- menced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoin (CBMG's "Off-the-Shelf" Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treat- ment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to sup- port pre-clinical studies of AlloJoin for Knee Osteoarthritis in the United States. To learn more about CBMG, visit www.cellbiomedgroup.com. OSIRIS THERAPEUTICS LAUNCHES PRESTIGE LYOTECHNOLOGY Osiris Therapeutics, Inc., a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics and sports medicine, announced that it has devel- oped cutting edge technology enabling the preservation of living cells and tis- sues at ambient temperatures. Historically, cryopreservation was the only available method that allowed for long-term preservation of living cells and tissues. However, cryopreservation requires ultra-low-temperature freezers and dry ice or liquid nitrogen for storage, which limits the widespread use of cellu- lar therapies. To address this limitation, Osiris has developed Prestige™ Lyotechnology. Unlike all other known lyophiliza- tion methods, Prestige Lyotechnology enables the preservation of living cells within tissues while stored at ambient temperatures. Moreover, the manufactur- ing of lyopreserved living tissues with Prestige Lyotechnology is scalable and can be applied to many different cell and tissue types. Placental products will be the focus of the company's first applica- tion of Prestige Lyotechnology. "This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercializa- tion and widespread use of living cell and tissue therapies," said Alla Danilkovitch, Chief Scientific Officer at Osiris. "Through more than two decades of basic and clinical research, Osiris has not only defined the science and poten- tial of cellular regenerative therapies, but has also created a body of work, advancing the medical community's understanding of cellular technology. With the introduction of Prestige Lyotechnology, Osiris is bringing these innovative cellular therapies to more patients to address a wide range of unmet medical needs." About Osiris Therapeutics Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine, including bio- engineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with prod- ucts in wound care, orthopedics and sports medicine, including Grafix ® , Stravix™, BIO4™, and Cartiform ® . Osiris, Grafix, Stravix and Cartiform are trademarks of Osiris Therapeutics, Inc., and BIO4 is a trademark of Howmedica Osteonics Corp. For more information, visit www.osiris.com.